Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. Show more
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 PR Newswire SAN DIEGO, Sept. 20, 2024 SAN DIEGO, Sept. 20, 2024 /PRNewswire/ -- Kintara...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.026 | 16.25 | 0.16 | 0.218 | 0.16 | 15625297 | 0.19405549 | CS |
4 | 0.0039 | 2.14168039539 | 0.1821 | 0.218 | 0.1553 | 4894508 | 0.18973239 | CS |
12 | -0.087 | -31.8681318681 | 0.273 | 0.2998 | 0.1553 | 2995584 | 0.2062696 | CS |
26 | 0.0914 | 96.6173361522 | 0.0946 | 0.417 | 0.0932 | 9669692 | 0.20961833 | CS |
52 | -3.814 | -95.35 | 4 | 4.5861 | 0.081 | 8463954 | 0.18096299 | CS |
156 | -42.564 | -99.5649122807 | 42.75 | 55 | 0.081 | 3729731 | 4.1148318 | CS |
260 | -60.314 | -99.6925619835 | 60.5 | 167.5 | 0.081 | 2939268 | 10.60547902 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.